NCT04018365

A Study of Empagliflozin in Patients With Refractory Diabetes Mellitus With Insulin Resistance

A Multicenter, Open-label, Single-arm Study With Regard to the Efficacy and Safety of Empagliflozin in Patients With Refractory Diabetes Mellitus With Insulin Resistance

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 8 (actual)
• Sponsor: Kobe University · Industry
• Sex: All
• Age: 20 Years
• Healthy volunteers: Not accepted

Summary

A multicenter, open-label, single-arm study with regard to the efficacy and safety of empagliflozin in patients with refractory diabetes mellitus with insulin resistance

Detailed description

To evaluate the clinical efficacy of a treatment with empagliflozin in refractory diabetes mellitus patients with insulin resistance (insulin resistance syndrome, lipoatrophic diabetes mellitus) by using the HbA1c change at Week 24 of treatment from baseline

Conditions

• Insulin Resistance - Type A
• Insulin Resistance - Type B
• Lipoatrophic Diabetes Mellitus
• Insulin Resistance Syndrome

Interventions

Type	Name	Description
DRUG	Empagliflozin Tablets	The administration is oral administration with water before or after breakfast.

Timeline

• Start date: 2019-09-01
• Primary completion: 2021-07-31
• Completion: 2021-10-30
• First posted: 2019-07-12
• Last updated: 2021-03-03

Locations

5 sites across 1 country: Japan